Manjishtha: Difference between revisions

Line 231:

{| class="wikitable"

! Target Domain !! Experimental Model !! Key Findings / Outcome ~~!! Citation~~

! Target Domain !! Experimental Model !! Key Findings / Outcome

|-

| '''Dermatology''' || In vitro / In vivo (Psoriasis Models) || Quinones (Alizarin, Purpurin) suppressed TNF-α-activated keratinocytes; reduced epidermal hyperplasia. || <ref name="Lin2025" />

| '''Dermatology''' || In vitro / In vivo (Psoriasis Models) || Quinones (Alizarin, Purpurin) suppressed TNF-α-activated keratinocytes; reduced epidermal hyperplasia.<ref name="Lin2025" />

|-

| '''Microbiology''' || In vitro Anti-acne assays || Ethanolic extracts inhibited ''C. acnes'' and ''S. epidermidis'' growth comparably to standard clindamycin gel formulations. || <ref name="Nipanikar2017" />

| '''Microbiology''' || In vitro Anti-acne assays || Ethanolic extracts inhibited ''C. acnes'' and ''S. epidermidis'' growth comparably to standard clindamycin gel formulations.<ref name="Nipanikar2017" />

|-

| '''Neuroprotection''' || STZ-induced Diabetic Rats || Attenuated neuropathic pain; lowered Bax:Bcl-2 apoptosis ratio and cleaved caspase-3 in sciatic nerves. || <ref name="Bana2023" />

| '''Neuroprotection''' || STZ-induced Diabetic Rats || Attenuated neuropathic pain; lowered Bax:Bcl-2 apoptosis ratio and cleaved caspase-3 in sciatic nerves.<ref name="Bana2023" />

|-

| '''Immunology''' || Inflammatory Skin Models (Lichen Planus) || Downregulated CD69 expression, reducing T-cell proliferation and serum IL-2/IFN-γ levels. ||

| '''Immunology''' || Inflammatory Skin Models (Lichen Planus) || Downregulated CD69 expression, reducing T-cell proliferation and serum IL-2/IFN-γ levels.

|-

| '''Antioxidant''' || Lipid Peroxidation Assays || Inhibited TBARS formation and scavenged free DPPH radicals in a dose-dependent manner. ||

| '''Antioxidant''' || Lipid Peroxidation Assays || Inhibited TBARS formation and scavenged free DPPH radicals in a dose-dependent manner.

|}

@@ Line 231: / Line 231: @@
 {| class="wikitable"
-! Target Domain !! Experimental Model !! Key Findings / Outcome !! Citation
+! Target Domain !! Experimental Model !! Key Findings / Outcome
 |-
-| '''Dermatology''' || In vitro / In vivo (Psoriasis Models) || Quinones (Alizarin, Purpurin) suppressed TNF-α-activated keratinocytes; reduced epidermal hyperplasia. || <ref name="Lin2025" />
+| '''Dermatology''' || In vitro / In vivo (Psoriasis Models) || Quinones (Alizarin, Purpurin) suppressed TNF-α-activated keratinocytes; reduced epidermal hyperplasia.<ref name="Lin2025" />
 |-
-| '''Microbiology''' || In vitro Anti-acne assays || Ethanolic extracts inhibited ''C. acnes'' and ''S. epidermidis'' growth comparably to standard clindamycin gel formulations. || <ref name="Nipanikar2017" />
+| '''Microbiology''' || In vitro Anti-acne assays || Ethanolic extracts inhibited ''C. acnes'' and ''S. epidermidis'' growth comparably to standard clindamycin gel formulations.<ref name="Nipanikar2017" />
 |-
-| '''Neuroprotection''' || STZ-induced Diabetic Rats || Attenuated neuropathic pain; lowered Bax:Bcl-2 apoptosis ratio and cleaved caspase-3 in sciatic nerves. || <ref name="Bana2023" />
+| '''Neuroprotection''' || STZ-induced Diabetic Rats || Attenuated neuropathic pain; lowered Bax:Bcl-2 apoptosis ratio and cleaved caspase-3 in sciatic nerves.<ref name="Bana2023" />
 |-
-| '''Immunology''' || Inflammatory Skin Models (Lichen Planus) || Downregulated CD69 expression, reducing T-cell proliferation and serum IL-2/IFN-γ levels. ||
+| '''Immunology''' || Inflammatory Skin Models (Lichen Planus) || Downregulated CD69 expression, reducing T-cell proliferation and serum IL-2/IFN-γ levels.
 |-
-| '''Antioxidant''' || Lipid Peroxidation Assays || Inhibited TBARS formation and scavenged free DPPH radicals in a dose-dependent manner. ||
+| '''Antioxidant''' || Lipid Peroxidation Assays || Inhibited TBARS formation and scavenged free DPPH radicals in a dose-dependent manner.
 |}